OMEICOS Therapeutics is a company that provides Health care, Pharmacy and Therapeutics, Mode of action and more. OMEICOS Therapeutics is headquartered in Germany Berlin. OMEICOS Therapeutics was founded in 2013. and was founded by Karen Uhlmann, Robert Fischer. OMEICOS Therapeutics has a total of 32 patents
Related Topics
Health carePharmacy and TherapeuticsMode of actionCardiovascular agentClinical trialAntiarrhythmic agentOrphan drugTherapeutic strategyDrug developmentHeart RhythmMetaboliteAtrial fibrillationDrug discoveryFatty acidMoleculeSmall moleculeDrugMacular edema
visualizing technology portfolio of hot application areas and blank areas for OMEICOS Therapeutics
Time Range:
Overall
Overall
1 year
3 year
5 year
Application Domain L2
Application Domain L2
Application Domain L3
Application Domain L4
High-Tech Industry L1
High-Tech Industry L2
Tech Topic L2
Tech Topic L3
Timeline
Tech Topic L2
Tech Topic L2
Tech Topic L3
High-Tech Industry L1
High-Tech Industry L2
Application Domain L2
Application Domain L3
Application Domain L4
Download
Subsidiary Lists
Subsidiaries with patent applications for OMEICOS Therapeutics
Sign up to view the full data
Free Trial Now
Download
Top Related Companies
Sign up to view the full data
Free Trial Now
OMEICOS Therapeutics Frequently Asked Questions
What is OMEICOS Therapeutics's industry?
OMEICOS Therapeutics is in the industry of:Pharmaceutical and Medicine ManufacturingResearch and Development in the Physical, Engineering, and Life Sciences
What technical fields has OMEICOS Therapeutics researched?
OMEICOS Therapeutics has researched the technical fields related toHealth carePharmacy and TherapeuticsMode of actionCardiovascular agentClinical trialAntiarrhythmic agentOrphan drugTherapeutic strategyDrug developmentHeart RhythmMetaboliteAtrial fibrillationDrug discoveryFatty acidMoleculeSmall moleculeDrugMacular edema
What is OMEICOS Therapeutics's total number of patents?
OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based...